

CANCER MARKET YEAR BOOK 2005

ISBN: 1 85822 251 6

© Copyright 2005 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library

FOREWORD	1
Key	2
GLOBAL OVERVIEW	3
Cancer Drugs Market	3
Cancer Drug R&D	3
Growth Drivers in the Cancer Drug Sector	3
Global Cancer Incidence	4
<i>Incidence of Cancer Worldwide by Cancer Site – 2002</i>	<i>5</i>
<i>Cancer Mortality Worldwide by Cancer Site – 2002</i>	<i>5</i>
Developed versus Developing Countries	6
<i>Regional Cancer Deaths as a Percentage of Total Deaths</i>	<i>6</i>
<i>Leading Causes of Death in the United States, 2002 (%)</i>	<i>6</i>
<i>Causes of Death in Brazil, 2001 (%)</i>	<i>7</i>
<i>Causes of Death in Pakistan, 2001 (%)</i>	<i>7</i>
<i>Global Cases of Selected Cancers, 2002</i>	<i>8</i>
<i>Global Deaths from Selected Cancers, 2002</i>	<i>8</i>
<i>Global Incidence of Selected Cancers per 100,000 Population, 2002</i>	<i>9</i>
<i>Global Death Rate per 100,000 Population from Selected Cancers, 2002</i>	<i>9</i>
<i>Estimated New Cases of Cancer in the USA, 2003-2005</i>	<i>10</i>
<i>2004 Revenues for Selected Leading Cancer Drugs, by Company</i> ..	<i>11</i>
<i>Selected Leading Cancer Drugs Ranked by 2003-2004 Revenue Growth</i>	<i>12</i>
BLADDER CANCER	13
OVERVIEW	13
PREVALENCE	14
<i>Cancer of the Bladder in Selected Countries, 2002</i>	<i>14</i>
<i>Deaths from Cancer of the Bladder in Selected Countries, 2002</i>	<i>15</i>
<i>Incidence of Cancer of the Bladder per 100,000 population, in Selected Countries in 2002</i>	<i>16</i>
<i>Death Rate from Cancer of the Bladder per 100,000 population, in Selected Countries in 2002</i>	<i>17</i>
BLADDER CANCER DRUGS IN USE	18
Companies & Products	19
Akzo Nobel	19
OncoTICE/TiceBCG	19
Eli Lilly	19
Gemzar	19
Pfizer	20
Farmorubicin/Pharmorubicin/Ellence	20
Sumitomo Chemical	21
Calsed	21
Wyeth	21
Thioplex	21
R&D PHASE III	22
Bristol-Myers Squibb	22
Javlor	22
GlaxoSmithKline	22
Tykerb	22
Intracel Resources	23
BCI-ImmuneActivator	23
R&D PHASE II	24
Bioenvision	24
Gossypol	24
Gloucester Pharmaceuticals	24
FK228 (depsipeptide)	24
PharmaMar	25
Aplidin	25
PhotoCure	25
Hexvix.....	25
Spectrum Pharmaceuticals	27
EOquin.....	27
INDUSTRY DEVELOPMENTS 2003/2004	28
Strategic Alliances in Bladder Cancer - June 2004 to December 2005	28
Significant Events in Bladder Cancer Drugs- June 2004 to December 2005	29
September 2004	29
PhotoCure gains approval for Hexvix in Sweden.....	29
Stellar receives Canadian approval to market NMP22 BladderChek	29
January 2005	29
FDA approves UroVysion for diagnosis of BC....	29
March 2005	30
PhotoCure's Hexvix approved in 26 European countries	30
June 2005	30
Hexvix NDA submitted to FDA.....	30
July 2005	30
Sanochemia acquires rights to innovative cancer diagnostic and treatments	30
NMP22 BladderChek receives marketing approval in Japan	31
BREAST CANCER	33
OVERVIEW	33
PREVALENCE	34
United States	34
<i>Cancer of the Breast in Selected Countries, 2002</i>	<i>35</i>
<i>Deaths from Cancer of the Breast in Selected Countries, 2002</i>	<i>36</i>
<i>Incidence of Cancer of the Breast per 100,000 population, in Selected Countries in 2002</i>	<i>37</i>
<i>Death Rate from Cancer of the Breast per 100,000 female population, in Selected Countries in 2002</i>	<i>38</i>
BREAST CANCER DRUGS IN USE	39
SERMs (selective oestrogen-receptor modulators)	39
Aromatase inhibitors	39
Biologic response modifiers	39
Other hormonal therapies	40
Chemotherapy	40

Adjuvant chemotherapy.....	40	IGN101	57
<i>Leading Branded Drugs Used in Breast Cancer – Sales 2002-2004/1</i>		AstraZeneca	58
Companies & Products	42	Faslodex	58
AEterna Zentaris	42	Biomira	58
Lobaplatin	42	Theratope	58
AstraZeneca	42	Bristol-Myers Squibb.....	60
Arimidex.....	42	Ixabepilone/BMS-310705	60
Nolvadex.....	43	Eli Lilly.....	60
Faslodex.....	44	Evista.....	60
Zoladex.....	44	Arzoxifene	60
Aventis.....	45	GlaxoSmithKline.....	61
Taxotere	45	Lapatinib (572016)	61
Bioenvision	46	Intarcia Therapeutics	61
Modrenal	46	Atamestane	61
Bristol-Myers Squibb.....	47	NeoPharm	62
Taxol.....	47	Liposome Encapsulated Doxorubicin (LED)	62
Megace.....	47	Novartis	62
BTG.....	48	Zometa	62
Zinecard	48	Femara.....	63
Daiichi.....	48	Pfizer.....	65
Topotecin	48	Lasofoxifene.....	65
Eli Lilly.....	48	Roche	66
Gemzar	48	Herceptin	66
GlaxoSmithKline.....	49	Xeloda.....	66
Navelbine.....	49	Avastin.....	67
Generic competition	49	sanofi-aventis	68
Merck.....	49	XRP9881/XRP6258	68
UFT	49	Schering	68
Novartis	50	MS-209.....	68
Femara.....	50	Wyeth	68
Lentaron.....	50	Temsilimus (CCI-779).....	68
Orion Pharma.....	50	YM BioSciences	69
Fareston	50	Tesmififene	69
Pfizer.....	51	R&D Phase II.....	70
Farmorubicin/Pharmorubicin/Ellence	51	AEterna Zentaris.....	70
Zavedos/Idamycin.....	51	Lobaplatin	70
Zinecard	52	AstraZeneca	70
Aromasin.....	52	Iressa.....	70
Roche	53	Attenuon	71
Herceptin	53	ATN-224.....	71
Xeloda.....	54	AVI BioPharma	71
Nolvadex.....	54	Oncomyc-NG	71
Schering-Plough.....	55	Bayer	72
Caelyx.....	55	BAY 59-8862 (IDN 5109)	72
Fareston	55	Biomira	72
Takeda	56	Theratope	72
Leuplin/Lupron/Enantone.....	56	Bristol-Myers Squibb.....	73
R&D - Phase III.....	57	Javlor	73
Alfacell	57	Cyclacel.....	73
Onconase	57	CYC202	73
Aphton.....	57	Cytokinetics	74

SB-715992	74	Vion Pharmaceuticals	91
SB-743921	75	Triapine	91
Eli Lilly.....	75	Xenova	92
Alimta	75	Tariquidar (XR9576)	92
Genta	75	Phase II – Others	93
Genasense	75	INDUSTRY DEVELOPMENTS 2003/2004.....	94
Genzyme Oncology	76	Strategic Alliances in Breast Cancer - June 2004	
Dendritic cell/cancer cell fusion vaccine	76	to December 2005	94
GlaxoSmithKline.....	77	Significant Events in Breast Cancer Drugs-	
SB-715992	77	June 2004 to December 2005.....	104
Introgen Therapeutics	77	June 2004	104
INGN 225	77	EC approves Herceptin+Taxotere as first-line	
Keryx Biopharmaceuticals	77	therapy in HER2-positive MBC	104
KRX-0403	77	FDA grants priority review for new indication of	
Kosan Biosciences.....	78	Femara.....	104
KOS-862/R1492.....	78	July 2004	104
Ligand Pharmaceuticals	79	Health Canada approves Arimidex for EBC.....	104
Targretin	79	August 2004	104
Pipendoxifene	80	Femara gains Swiss approval as only post-	
Lorus Therapeutics.....	80	tamoxifen treatment for EBC.....	104
GTI-2040.....	80	FDA approves Aventis' Taxotere for the	
Medarex	80	treatment of early BC.....	105
MDX-010.....	80	September 2004	105
Micromet	81	FDA accepts Bonefos for filing and grants priority	
MT201	81	review in treatment of bone metastases of BC .	105
Millenium Pharmaceuticals.....	82	October 2004	106
Velcade.....	82	Femara gains FDA approval as post-tamoxifen	
NeoPharm	82	treatment for EBC.....	106
LE-SN38	82	November 2004	106
Liposome Encapsulated Doxorubicin (LED)	83	New ASCO recommendation for postmenopausal	
Novartis	83	women with EBC	106
Sandostatin	83	New tamoxifen pathway may lead to improved	
PTK787.....	84	BC treatments	107
OSI Pharmaceuticals	84	December 2004	107
Tarceva	84	Gemzar+Taxol combination receives UK	
Oxford BioMedica.....	85	approval for MBC.....	107
MetXia	85	January 2005.....	107
OXIGENE	86	Savient submits NDA for Soltamox to FDA.....	107
Combretastatin A4P	86	FDA issues approvable letter for Bonefos	107
PharmaMar	87	FDA approves Abraxane for MBC.....	108
Yondelis	87	Taxotere receives two new European approvals	
Roche	87	for BC treatment.....	108
Tarceva	87	February 2005.....	108
Omnitarg.....	87	FDA approves BioGenex' InSite HER2/neu kit ...	108
R1492	88	UK Court of Appeal finds Pfizer's epirubicin	
Herceptin	88	patent infringed by Mayne.....	108
Avastin.....	90	March 2005.....	109
sanofi-aventis	90	Femara approved in Germany in extended	
XRP6258/XRP9881	90	adjuvant setting	109
Telik.....	91	Taxol receives approval in Europe for adjuvant	
Telcyta	91	treatment	109

April 2005	110	November 2005	116
Health Canada approves Novartis' Femara for extended adjuvant treatment of BC	110	Agendia's MammaPrint receives CE registration.....	116
May 2005	110	US Court of Appeals affirms dismissal of tamoxifen antitrust lawsuits	116
TriPath receives FDA clearance for OR and PR applications for VIAS	110	December 2005	116
Applied Imaging gains FDA clearance for BC patient selection application.....	110	Femara approved by MHRA for post-surgery use in early invasive BC.....	116
Further trial data required for Bonefos NDA.....	110	COLORECTAL CANCER	117
June 2005	110	OVERVIEW	117
Kyowa obtains additional approval for Navelbine	110	PREVALENCE	118
NDS for Abraxane filed in Canada for MBC	110	<i>Cancer of the Colon and Rectum in Selected Countries, 2002</i>	118
Arimidex approved in UK for early adjuvant treatment.....	111	<i>Deaths from Cancer of the Colon and Rectum in Selected Countries, 2002</i>	119
July 2005	111	<i>Incidence of Cancer of the Colon and Rectum per 100,000 population, in Selected Countries in 2002</i>	120
Novartis submits US and European applications for Femara	111	<i>Death Rate from Cancer of the Colon and Rectum per 100,000 population, in Selected Countries in 2002</i>	121
August 2005	112	COLORECTAL CANCER DRUGS IN USE	122
TriPath receives FDA 510(k) clearance for HER2 /neu application for VIAS.....	112	Antimetabolites	122
Takeda obtains approval of additional indication for Leuplin SR for injection kit 11.25.....	112	Platinum analogs	122
Femara granted FDA priority review for new indication.....	112	Topoisomerase Inhibitors	123
Genentech provides updated cardiotoxicity data related to Herceptin.....	112	Monoclonal antibodies	123
September 2005	113	Companies & Products	125
Agendia acquires ISO accreditation for MammaPrint test	113	AstraZeneca	125
Pfizer receives European approval to market Aromasin for adjuvant treatment of early BC in postmenopausal women.....	113	Tomudex	125
Arimidex gains full FDA approval for adjuvant treatment of hormone receptor-positive EBC in postmenopausal women.....	113	sanofi-aventis	125
October 2005	114	Campto.....	125
FDA approves BioGenex InSite HER2/neu (CB11) MAb.....	114	Bristol-Myers Squibb / ImClone / Merck KGaA	126
Pfizer receives FDA approval of Aromasin for the adjuvant treatment of early BC in postmenopausal women.....	114	Eribitux	126
Allos withdraws European MAA for Revaproxyn	114	<i>Colorectal cancer</i>	128
St Gallen BC panel recommends sequential treatment for postmenopausal women with hormone-sensitive early BC	115	BTG	129
Veridex receives additional 510(k) clearance for the CellSearch circulating tumour cell kit.....	115	Tomudex	129
Savient receives FDA approval to market Soltamox.....	115	Daiichi	129
		Topotecin	129
		Merck KGaA	130
		Eribitux	130
		UFT	130
		Pfizer	130
		Camptosar	130
		Celebrex/Celebra/Onsenal	131
		Roche	132
		Xeloda.....	132
		Avastin.....	132
		sanofi-aventis	133
		Eloxatin.....	133
		R&D – PHASE III	135
		Abgenix	135
		Panitumumab	135
		Colorectal cancer.....	135
		ADVENTRX Pharmaceuticals	136

CoFactor	136	Erbitux	158
Aphton	138	<i>Colorectal cancer</i>	<i>159</i>
IGN101	138	IDM Pharma	160
ImClone Systems / Bristol-Myers Squibb / Merck		EP-2101	160
KGaA	138	Collidem.....	160
Erbitux	138	Immunomedics	161
<i>Colorectal cancer</i>	<i>139</i>	IMMU-100, IMMU-111	161
Novartis	140	Keryx Biopharmaceuticals	162
PTK787.....	140	KRX-0402	162
Pfizer	141	Kosan Biosciences	162
Camptosar	141	KOS-862/R1492	162
Roche	142	KuDOS Pharmaceuticals	163
Avastin.....	142	Patrin	163
Xeloda.....	143	Lorus Therapeutics	164
Schering	144	GTI-2040.....	164
ZK 222584	144	MedImmune	165
Leukine.....	145	Vitaxin	165
R&D – PHASE II	146	Mediatech Research	165
Abgenix	146	HyCAMP	165
Panitumumab.....	146	Merck KGaA	167
Colorectal cancer.....	146	Erbitux	167
Antigenics	147	<i>Colorectal cancer</i>	<i>168</i>
Oncophage (HSPPC-96).....	147	EMD 273066/EMD 273063	169
Aroplatin	147	NeoPharm	170
AVI BioPharma	148	LE-SN38	170
Avicine	148	Oxford BioMedica	170
Oncomyc-NG	149	TroVax.....	170
Bayer	149	OXIGENE	172
BAY 43-9006.....	149	Combretastatin A4P	172
Biomira	150	PharmaMar	173
Theratope	150	Aplidin.....	173
Can-Fite BioPharma	151	sanofi-aventis	174
CF101	151	Cancer vaccines/ALVAC-CEA/B7.1	174
Cell Therapeutics	152	Schering	174
Xyotax.....	152	MS-275.....	174
PG-CPT.....	153	Telik	175
Cephalon	154	Telcyta	175
Trisenox.....	154	Therion	176
Cytokinetics	154	ALVAC-CEA/B7.1	176
Ispinesib.....	154	Willex	177
Eli Lilly	155	WX-UK1	177
Alimta	155	Phase II – Others	178
Vitaxin	155	INDUSTRY DEVELOPMENTS 2004/2005	179
Genta	156	Strategic Alliances in Colorectal Cancer - June	
Genasense	156	2004 to December 2005	179
GenVec	156	Significant Events in Colorectal Cancer Drugs- June	
TNFerade.....	156	2004 to December 2005	184
GlaxoSmithKline	157	June 2004	184
Ispinesib.....	157	Pfizer to acquire Campto following merger of	
ImClone Systems / Bristol-Myers Squibb / Merck		Sanofi-Synthélabo and Aventis	184
KGaA	158		

Erbitux approved for launch in Europe to treat
MCRC..... 184

AUGUST 2004 184

Roche files Xeloda in Europe and the US for the
treatment of CC after surgery 184

September 2004 185

Eloxatin to gain expanded indication for treatment
of early-stage MCRC in Europe 185

October 2004 185

Pfizer acquires Campto in the UK..... 185

November 2004 185

Eloxatin receives FDA approval for adjuvant
treatment of CC..... 185

January 2005..... 186

Avastin approved in the EU 186

February 2005..... 186

sanofi-aventis receives FDA approval for new
Eloxatin formulation..... 186

March 2005..... 187

Inverness/Wampole launch new tool for CRC
screening 187

April 2005 187

Xeloda wins EU approval for adjuvant therapy
in the treatment of colon cancer 187

June 2005 187

FDA approves oral Xeloda for the adjuvant
treatment of CC..... 187

July 2005 188

NICE issues final determination on CRC drugs .. 188

August 2005 188

Xeloda approved by the SMC for use in the
adjuvant treatment of CC 188

Beckman introduces Hemocult ICT for colorectal
cancer screening 188

August 2005 189

NICE extends its recommendations for the use of
drugs for the treatment of advanced CRC..... 189

September 2005 189

Health Canada approves Avastin for CRC..... 189

Health Canada approves Erbitux for the
treatment of MCRC..... 189

October 2005 189

Preliminary NICE recommendations favour
Eloxatin and Xeloda for Stage III CC patients 189

November 2005 190

SMC approves Eloxatin for CC 190

December 2005..... 190

Genzyme launches CRC test to determine
appropriate Camptosar dosage 190

KIDNEY CANCER..... 191

OVERVIEW 191

PREVALENCE 192

Cancer of the Kidney in Selected Countries, 2002..... 192

Deaths from Cancer of the Kidney in Selected Countries, 2002..... 193

*Incidence of Cancer of the Kidney per 100,000 population, in
Selected Countries in 2002 194*

*Death Rate from Cancer of the Kidney per 100,000 population,
in Selected Countries in 2002 195*

KIDNEY CANCER DRUGS IN USE 196

Chiron 196

Proleukin..... 196

Roche 197

Roferon-A 197

New formulations 198

Sumitomo Chemical 198

Sumiferon 198

Shionogi 198

Imunace (S-6820) 198

R&D PHASE III 199

Antigenics 199

Oncophage (HSPPC-96)..... 199

Bayer 200

Nexavar 200

Celgene..... 200

Thalomid 200

GlaxoSmithKline..... 201

Tykerb 201

Pfizer..... 201

Sutent 201

Roche 202

Avastin..... 202

Wyeth 204

Temsirolimus (CCI-779)..... 204

R&D PHASE II..... 205

Abgenix 205

ABX-EGF 205

Biomira 205

L-IL-2..... 205

Coley Pharmaceutical..... 206

PF-3512676 206

Genta 206

Genasense 206

Idera Pharmaceuticals 207

IMOXine..... 207

OSI Pharmaceuticals 209

OSI-461 209

Renal Cell Carcinoma (RCC)..... 209

Pharmacyclics 210

Xcytrin 210

PharmaMar 211

Aplidin 211

Phase II – Others 212

INDUSTRY DEVELOPMENTS 2003/2004	213	Protherics	231
Strategic Alliances in Kidney Cancer - June		Prolarix	231
2004 to December 2005	213	sanofi-aventis	232
Significant Events in Kidney Cancer Drugs-		Alvocidib (flavopiridol).....	232
June 2004 to December 2005	214	SciClone Pharmaceuticals	232
July 2005	214	Zadaxin	232
Bayer and Onyx complete filing of NDA for		Transgene	233
sorafenib for treatment of advanced RCC	214	Ad-IFNg (TG1042)	233
August 2005	214	Phase II – Others	234
Pfizer submits NDA for Sutent	214	INDUSTRY DEVELOPMENTS 2003/2004	235
September 2005	215	Strategic Alliances in Liver Cancer - June 2004 to	
Bayer/Onyx submit sorafenib MAA for		December 2005	235
treatment of RCC	215	Significant Events in Liver Cancer Drugs-	
FDA accepts NDA submission for sorafenib in		June 2004 to December 2005	236
RCC	215	October 2004	236
LIVER CANCER	217	Primovist MRI liver contrast agent approved in	
OVERVIEW	217	the EU	236
PREVALENCE	218	LUNG CANCER	237
<i>Cancer of the Liver in Selected Countries, 2002</i>	218	OVERVIEW	237
<i>Deaths from Cancer of the Liver in Selected Countries, 2002</i>	219	Small Cell Lung Cancer	237
<i>Incidence of Cancer of the Liver per 100,000 population, in</i>		Non-small Cell Lung Cancer	237
<i>Selected Countries in 2002</i>	220	Other Types of Lung Cancer	237
<i>Death Rate from Cancer of the Liver per 100,000 population, in</i>		Prevalence	238
<i>Selected Countries in 2002</i>	221	<i>Cancer of the Lung in Selected Countries, 2002</i>	238
LIVER CANCER DRUGS IN USE	222	<i>Deaths from Cancer of the Lung in Selected Countries, 2002</i>	239
Chemotherapy	222	<i>Incidence of Cancer of the Lung per 100,000 population, in</i>	
Chemoembolisation	222	<i>Selected Countries in 2002</i>	240
R&D – PHASE III	223	<i>Death Rate from Cancer of the Lung per 100,000 population, in</i>	
Bayer	223	<i>Selected Countries in 2002</i>	241
Nexavar	223	LUNG CANCER DRUGS IN USE	242
EXIMIAS Pharmaceutical	223	Chemotherapy	242
Thymitaq.....	223	EGFR anatgonists	242
Tularik	224	Photodynamic therapy	242
T67 (batabulin).....	224	Companies and Products	243
R&D – PHASE II	226	AEterna Zentaris	243
Attenuon	226	Lobaplatin	243
ATN-224.....	226	AstraZeneca	243
Bristol-Myers Squibb	226	Iressa.....	243
Ixabepilone/BMS-310705	226	Aventis	245
Genzyme	227	Taxotere	245
DENSPM	227	Bristol-Myers Squibb	245
Immunomedics	227	Taxol.....	245
IMMU-105	227	Generic competition	246
MGI Pharma	227	Paraplatin	247
Irofulven.....	227	Etopophos	247
Novartis	229	Daiichi	248
Sandostatin	229	Topotecin	248
PharmaMar	230	Eli Lilly	248
Kahalalide F	230	Gemzar	248
Progen Industries	230	GlaxoSmithKline	249
PI-88.....	230	Hycamtin.....	249

Navelbine.....	249	R&D PHASE II.....	277
Generic competition.....	250	Abgenix	277
Kyowa Hakko	250	Panitumumab.....	277
Navelbine.....	250	Non-small cell lung cancer	277
Sumitomo Chemical	250	AEterna Zentaris	277
Calsed	250	Lobaplatin	277
R&D – PHASE III	251	RC-3095	278
AEterna Zentaris	251	AnorMED	278
Neovastat.....	251	NX473	278
Alfacell	252	Antigenics	279
Onconase	252	Oncophage (HSPPC-96).....	279
Ranpirnase Conjugates and Fusion Proteins.....	254	QS-21.....	279
Evaluation of Onconase as A Radiation Enhancer.....	254	Attenuon	280
Onconase As a Resistance–Overcoming and Apoptosis- Enhancing Agent.....	255	ATN-224.....	280
Allos Therapeutics	255	AVI BioPharma	280
Efaproxyn	255	Oncomyc-NG	280
RSR13 in the treatment of NSCLC	255	Bayer	281
Bristol-Myers Squibb	256	BAY 59-8862 (IDN 5109)	281
Javlor	256	Biomira	281
Cell Therapeutics	257	L-BLP25.....	281
Xyotax.....	257	BioNumerik Pharmaceuticals	283
Coley Pharmaceutical	260	Karenitecin BNP1350	283
PF-3512676	260	Bristol-Myers Squibb / ImClone / Merck KGaA	283
Genta	261	Erbitux	283
Genasense	261	Cephalon	285
GlaxoSmithKline	262	SDX-102	285
Hycamtin.....	262	Cyclacel	285
Tykerb.....	262	Seliciclib	285
Igeneon	263	Cytokinetics	286
IGN101	263	Ispinesib.....	286
ImClone Systems	263	Epimmune	287
Erbitux	263	EP-2101	287
<i>Erbitux in Non-Small Cell Lung Cancer (NSCLC) Phase II & III Trials,</i> <i>March 2005</i>	264	GlaxoSmithKline	288
Ligand Pharmaceuticals	264	Mage 3 (249553)	288
Targretin	264	Ispinesib.....	288
Capsule formulation	265	SB-715992	289
OSI Pharmaceuticals	266	Idera Pharmaceuticals	289
Tarceva	266	IMOXine.....	289
OXIGENE	270	ImmunoGen	291
Combretastatin A4P	270	huN901-DM1	291
Pharmacyclics	271	INEX Pharmaceuticals	292
Xcytrin	271	Marqibo.....	292
Roche	273	Introgen Therapeutics	292
Tarceva	273	Advexin	292
Avastin.....	274	Lung cancer.....	293
Schering	275	INGN 225	293
MS-209.....	275	INGN 401	294
Telik	275	Keryx Biopharmaceuticals	294
Telcyta	275	KRX-0403	294
		Kosan Biosciences	294
		KOS-862/R1492	294

Ligand Pharmaceuticals	295	Alimta receives positive endorsement for LC approval from ODAC.....	317
Panretin.....	295	August 2004	318
Lorus Therapeutics	295	OSI/Genentech complete NDA for FDA approval of Tarceva	318
GTI-2040	295	FDA approves Lilly's Alimta for the second-line treatment of advanced NSCLC.....	318
MedImmune	296	Roche files MAA for European approval of Tarceva to treat advanced NSCLC	319
Ethyol	296	September 2004	319
Merck KGaA	297	Alimta approved in the EU for two cancer indications	319
EMD 273066/EMD 273063	297	FDA grants fast track status for BLP25 Liposome Vaccine	320
Millenium Pharmaceuticals	297	Tarceva NDA accepted for FDA review	320
Velcade.....	297	November 2004	320
NeoPharm	298	Alimta approved in UK as first licensed treatment for mesothelioma.....	320
LE-SN38	298	FDA approves Tarceva for advanced NSCLC.....	320
Novacea	299	OSI launches Tarceva	321
DN-101	299	January 2005	321
Pfizer	300	Iressa MAA withdrawn in EU	321
Celebrex/Celebra/Onsenal	300	March 2005	321
Prinomastat.....	301	Tarceva receives first European approval for NSCLC	321
CI-1033.....	301	April 2005	321
CP-547,632	301	APP receives approval for vinorelbine	321
PharmaMar	302	May 2005	322
Aplidin	302	Fujirebio submits application to FDA for approval of Mesomark	322
Kahalalide F	302	CeMines files 510(k) application with FDA for LC detection kit	322
Progen Industries	303	June 2005	322
PI-88.....	303	Tarceva receives positive EU opinion for advanced NSCLC	322
Roche	304	July 2005	322
Omnitarg.....	304	Tarceva granted approval in Canada for treatment of advanced NSCLC	322
sanofi-aventis	304	August 2005	323
Meclinetant.....	304	SMC accepts pemetrexed for restricted use in the treatment of mesothelioma.....	323
Schering	305	Sanyo launches diagnostic for small cell lung cancer	323
MS-275	305	September 2005	323
ZK 222584	305	Tarceva approved in Europe for NSCLC.....	323
SuperGen	305	Genzyme launches exclusive NSCLC test.....	324
Orathecin	305	CeMines Estonia files CE mark registration seeking clearance to distribute Cell Correct LAB	324
Telik	306	October 2005	325
Telcyta	306	Oncotech offers new genomic test for LC.....	325
Transgene	306	NCCN releases updated treatment guidelines for	
MVA-MUC1-IL2 (TG4010)	306		
Vion Pharmaceuticals	308		
Triapine	308		
Phase II – Others	310		
INDUSTRY DEVELOPMENTS 2003/2004	311		
Strategic Alliances in Lung Cancer - June 2004 to December 2005	311		
Significant Events in Lung Cancer Drugs- June 2004 to December 2005	317		
June 2004	317		
Alimta receives CHMP positive opinion for MPM and LC	317		
Tarceva accepted into FDA's Pilot 1 Program	317		
July 2004	317		

NSCLC	325	Bayer	349
OVARIAN CANCER	327	BAY 59-8862 (IDN 5109)	349
OVERVIEW	327	BioNumerik Pharmaceuticals	349
PREVALENCE	328	Karenitecin BNP1350	349
<i>Cancer of the Ovaries in Selected Countries, 2002</i>	328	Bristol-Myers Squibb	350
<i>Deaths from Cancer of the Ovaries in Selected Countries, 2002</i>	329	Javlor	350
<i>Incidence of Cancer of the Ovaries per 100,000 population, in Selected Countries in 2002</i>	330	Cell Therapeutics	350
<i>Death Rate from Cancer of the Ovaries per 100,000 female population, in Selected Countries in 2002</i>	331	PG-CPT.....	350
OVARIAN CANCER DRUGS IN USE	332	Cytokinetics	351
Companies & Products	333	Ispinesib	351
Aventis	333	Eli Lilly	351
Taxotere	333	Alimta	351
Bristol-Myers Squibb	333	Endocyte	352
Taxol.....	333	FolateScan	352
Markets/indications.....	334	Marshall Edwards	352
Agreements.....	334	Phenoxodiol	352
Generic competition	334	Merck KGaA	354
Paraplatin	335	EMD 72000	354
Megace	336	EMD 273066/EMD 273063	354
Daiichi	336	MGI Pharma	355
Topotecin	336	Irofulven.....	355
Eli Lilly	337	OXIGENE	356
Gemzar	337	Combretastatin A4P	356
GlaxoSmithKline	338	Novartis	357
Hycamtin.....	338	PTK787.....	357
MGI Pharma	338	Pfizer	357
Hexalen Capsules	338	CP-547,632	357
Schering-Plough	339	Roche	358
Caelyx	339	Omnitarg.....	358
R&D – PHASE III	340	Wilex	358
AltaRex	340	WX-UK1	358
OvaRex MAb.....	340	Phase II – Others	359
Cell Therapeutics	341	INDUSTRY DEVELOPMENTS 2003/2004	360
Xyotax.....	341	Strategic Alliances in Ovarian Cancer - June 2004 to December 2005	360
GlaxoSmithKline	343	Significant Events in Ovarian Cancer Drugs- June 2004 to December 2005	363
Hycamtin.....	343	July 2004	363
PharmaMar	343	Gemzar+carboplatin receives EU approvals to treat OC.....	363
Yondelis	343	October 2004	363
Roche	344	Bedford receives approval for carboplatin injection	363
Avastin.....	344	APP and Pharmachemie gain approval for carboplatin for injection	364
Telik	345	APP receives approval for carboplatin injection.....	364
Telcyta	345	February 2005	364
R&D – PHASE II	347	FDA grants full approval to Doxil following submission of Phase III data.....	364
Access Pharmaceuticals	347	Mayne adds carboplatin 600mg/60mL injection to its product line	365
AP5280	347		
Apton	348		
GnRH pharmacine	348		
AVAX Technologies	348		
O-Vax	348		

May 2005	365	R&D – PHASE II	387
NICE issues guidance for treatment of advanced OC	365	Antigenics	387
July 2005	366	Oncophage (HSPPC-96).....	387
Mayne receives FDA approval for multi-dose carboplatin	366	QS-21	387
September 2005	366	Biomira	388
IBEX launches OC hK6 assay for research purposes	366	Enhanzyn	388
PANCREATIC CANCER.....	367	Cell Genesys	388
OVERVIEW	367	GVAX cancer vaccines.....	388
PREVALENCE	368	GVAX Pancreatic Cancer Vaccine	388
<i>Cancer of the Pancreas in Selected Countries, 2002</i>	<i>368</i>	Genta	389
<i>Deaths from Cancer of the Pancreas in Selected Countries, 2002 ...</i>	<i>369</i>	GenVec.....	390
<i>Incidence of Cancer of the Pancreas per 100,000 population, in</i> <i>Selected Countries in 2002</i>	<i>370</i>	TNFerade.....	390
<i>Death Rate from Cancer of the Pancreas per 100,000 population,</i> <i>in Selected Countries in 2002</i>	<i>371</i>	GlycoGenesys.....	391
PANCREATIC CANCER DRUGS IN USE.....	372	GCS-100	391
Companies & Products	373	Kyowa Hakko	392
Bristol-Myers Squibb.....	373	KT5555/CEP-701	392
Erbixutux	373	NeoPharm	393
Eli Lilly	373	LE-SN38	393
Gemzar	373	Novartis	394
Markets/indications.....	373	PTK787.....	394
SuperGen	374	Oxford BioMedica.....	394
Mitozytrex	374	MetXia	394
R&D – PHASE III	375	Peregrine Pharmaceuticals	395
Aphthon.....	375	Cotara	395
Insegia	375	PharmaMar	395
AVI BioPharma	378	Aplidin	395
Avicine	378	Cephalon	396
Daiichi Sankyo	378	SDX-102	396
Eli Lilly.....	379	SuperGen	396
Alimta	379	Orathecin/CZ 112.....	396
ImClone Systems	379	Vion Pharmaceuticals	398
Erbixutux	379	Triapine	398
<i>ImClone Systems Pancreatic Cancer Trial</i>	<i>379</i>	Wilex	399
Lorus Therapeutics.....	380	WX-UK1	399
Virulizin	380	Phase II – Others	400
OSI Pharmaceuticals	382	INDUSTRY DEVELOPMENTS 2003/2004.....	401
Tarceva	382	Strategic Alliances in Pancreatic Cancer - June 2004 to December 2005.....	401
Roche	383	Significant Events in Pancreatic Cancer Drugs- June 2004 to December 2005.....	403
Avastin.....	383	June 2004	403
sanofi-aventis	383	Aphthon begins regulatory submission in Switzerland for G17DT monotherapy in PC.....	403
Eloxatin.....	383	July 2004	403
SuperGen	384	EuroGen files MAA for approval of Orathecin to treat PC.....	403
Orathecin/CZ 112.....	384	August 2004.....	403
Avicine	385	Aphthon submits regulatory application in Canada for Insegia	403
Therion Biologics.....	386	May 2005	404
Panvac	386	OSI files sNDA for Tarceva in PC	404

June 2005	404	Abbott	422
FDA agrees to rolling NDA for Virulizin	404	Xinlay	422
July 2005	405	Cell Genesys	423
FDA accepts Tarceva sNDA in PC.....	405	GVAX cancer vaccines.....	423
September 2005	405	GVAX Prostate Cancer Vaccine	423
ODAC recommends Tarceva for PC	405	Dendreon	425
November 2005	405	Provenge.....	425
Tarceva receives FDA approval for treatment of		GlaxoSmithKline	428
advanced PC in combination with		Avodart.....	428
gemcitabine	405	GPC Biotech	428
PROSTATE CANCER	407	Satraplatin	428
OVERVIEW	407	GTx	430
PREVALENCE	408	Acapodene	430
<i>Cancer of the Prostate in Selected Countries, 2002</i>	408	Northwest Biotherapeutics	431
<i>Deaths from Cancer of the Prostate in Selected Countries, 2002</i>	409	DCVax-Prostate	431
<i>Incidence of Cancer of the Prostate per 100,000 population, in</i>		Novacea	431
<i>Selected Countries in 2002</i>	410	DN-101	431
<i>Death Rate from Cancer of the Prostate per 100,000 male</i>		Novartis	432
<i>population, in Selected Countries in 2002</i>	411	Glivec/Gleevec	432
PROSTATE CANCER DRUGS IN USE	412	Spectrum Pharmaceuticals	433
Chemotherapy	412	Satraplatin	433
Hormonal therapy	412	R&D – PHASE II	434
Companies & Products	413	Abgenix	434
Abbott	413	ABX-EGF	434
Lupron Depot/Lucrin.....	413	AEterna Zentaris	434
Amgen	413	Ozarelix	434
AstraZeneca	413	Teverelix.....	435
Zoladex.....	413	RC-3095	435
Zoladex LA.....	414	Neovastat.....	436
Casodex.....	414	AnorMED	436
Aventis	416	NX473	436
Suprefact/Suprecur	416	Aphton	437
Anandron/Nilandron.....	416	GnRH pharmacine.....	437
Bayer	416	Attenuon	438
Viadur	416	ATN-224.....	438
OSI Pharmaceuticals	417	AVI BioPharma	438
Novantrone	417	Oncomyc-NG	438
Pfizer	417	Bioenvision	439
Estracyt.....	417	Abetafen	439
Praecis Pharmaceuticals	417	Modrenal	439
Plenaxis	417	Gossypol	439
sanofi-aventis	419	Celgene	440
Eligard	419	Actimid	440
Schering	420	Thalomid.....	440
Androcur	420	Eli Lilly	441
Schering-Plough	420	Vitaxin	441
Eulexin.....	420	EntreMed	441
Generic competition	420	Panzem.....	441
Takeda	421	Genta	442
Leuplin/Lupron/Enantone.....	421	Genasense	442
R&D – PHASE III	422	GlaxoSmithKline	443

GnRH pharmacine	443	EU approves Taxotere for PCA	470
ImmunoGen	444	New caesium-131 treatment used in prostate cancer	470
MLN2704	444	December 2004	470
Micromet	445	Abbott submits Xinlay NDA for advanced PCA .	470
MT201	445	FDA approves Eligard six-month formulation for PCA.....	470
Millenium Pharmaceuticals	445	Praecis issued draft national coverage determination for Plenaxis.....	471
Velcade.....	445	Eligard gains approvals in 24 European countries	471
MLN2704/MLN591RL	446	Signet expands product portfolio for 2005	471
NeoPharm	447	February 2005	472
LE-SN38	447	FDA agrees to file Abbott's NDA for Xinlay.....	472
Liposome Encapsulated Doxorubicin (LED)	447	Expert report highlights use of combination therapy for PCA.....	472
Northwest Biotherapeutics	448	Eligard 45mg launched in US for advanced PCA.....	473
MDX-070	448	Sosei files MAA for SOT-375	473
Novartis	448	March 2005	473
PTK787.....	448	Praecis' obtains NCD to allow consistent access to Plenaxis in US	473
Oncolytics Biotech	449	Praecis provides update on MAA for Plenaxis in Germany	474
Reolysin.....	449	Tessera launches new PCA test.....	474
Onyvax	451	April 2005	475
Onyvax-P.....	451	Watson launches Trelstar Depot and Trelstar LA	475
OSI Pharmaceuticals	452	June 2005	475
OSI-461	452	Oncura introduces RAPID Strand Rx.....	475
Hormone-Refractory Prostate Cancer (HRPCA)	452	Valera commences regulatory filing process for European approvals of Vantas.....	475
OXIGENE	453	August 2005	476
Combretastatin A4P	453	Theragenics restructures to focus on core business units	476
PharmaMar	454	Dendreon signs agreement to lease manufacturing facility in NJ	476
Aplidin	454	September 2005	476
Procyon Biopharma	454	ODAC does not recommend Xinlay HRPCA treatment.....	476
PCK3145	454	Dendreon to submit Provenge BLA for the treatment of advanced PCA	476
Roche	456	Praecis gains German approval for Plenaxis; Schering collaboration terminated	477
Omnitarg.....	456	October 2005	477
sanofi-aventis	456	Abbott receives not-approvable letter for Xinlay	477
SR 31747	456	November 2005	478
Therion	456	MediGene to receive milestone payment for launch of Eligard in Spain	478
PROSTVAC-VF/TRICOM.....	456	Valera receives marketing authorisation in Denmark for Vantas.....	478
YM BioSciences	457		
Tesmilifene	457		
Norelin.....	458		
Phase II – Others	460		
INDUSTRY DEVELOPMENTS 2003/2004	461		
Strategic Alliances in Prostate Cancer - June 2004 to December 2005	461		
Significant Events in Prostate Cancer Drugs- June 2004 to December 2005	469		
July 2004	469		
Atrix' Eligard six-month PCA product submitted for Canadian marketing authorisation	469		
Paladin files NDS for Histrelin Hydrogel Implant.....	469		
October 2004	469		
FDA approves Valera's Vantas PCA implant	469		
November 2004	470		

December 2005.....	478
GPC begins rolling NDA submission for satraplatin.....	478
QLT reports partial result in Eligard patent litigation.....	478
BIBLIOGRAPHY	479